Augusto Maria Lavalle Cobo
@otamendi.com.ar
Chief Department of Cardiology/ MD
Sanatorio Otamendi
EDUCATION
Graduate degree Cardiologist. Universidad de Buenos Aires.
RESEARCH, TEACHING, or OTHER INTERESTS
Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
Scopus Publications
Scopus Publications
Walter Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle-Cobo, and Juan P. Nogueira
Elsevier BV
Dirk Sibbing, Michael J Blaha, Rajinder Chawla, Augusto Lavalle-Cobo, Amit Kishore, Angel Lanas, Li Li, Francesca Santilli, Oliver Schnell, and Zhongwei Shi
Radcliffe Media Media Ltd
Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy, safety and net clinical benefit (NCB) of DPI with aspirin. Methods: PubMed and Embase were searched for randomised controlled trials reporting clinical efficacy, safety and NCB of DPI compared with aspirin alone in patients with coronary artery disease (CAD) and/or peripheral artery disease. Six articles representing four trials were included. Results: DPI versus aspirin alone significantly reduced major adverse cardiovascular events (HR 0.77; 95% CI [0.69–0.87]; p<0.01), increased International Society on Thrombosis and Haemostasis major bleeding events (HR 1.67; 95% CI [1.37–2.02]; p<0.01) and resulted in a significant NCB (HR 0.79; 95% CI [0.70–0.90]; p<0.01). Conclusion: These results underscore the potential benefit of DPI in patients with CAD, including those in the immediate post-acute coronary syndrome stage and with established CAD, as well as patients with peripheral artery disease.
Augusto Lavalle Cobo, Walter Masson, Martin Lobo, Leandro Barbagelata, Ezequiel Forte, Pablo Corral, and Juan P Nogueira
Elsevier BV
Walter Masson, Leandro Barbagelata, Augusto Lavalle-Cobo, Pablo Corral, and Juan P. Nogueira
Springer Science and Business Media LLC
Walter Masson, Leandro Barbagelata, Martín Lobo, Gabriela Berg, Augusto Lavalle-Cobo, and Juan P. Nogueira
Springer Science and Business Media LLC
Walter Masson, Leandro Barbagelata, Juan P Nogueira, Pablo Corral, Augusto Lavalle-Cobo, and Francisco J. Romeo
XMLink
Objective The role of lipoprotein(a) (Lp[a]) as a possibly causal risk factor for atherosclerotic cardiovascular disease has been well established. However, the clinical evidence regarding the association between Lp(a) levels and atrial fibrillation (AF) remains limited and inconsistent. This study aimed to analyze the association between elevated Lp(a) levels or single-nucleotide polymorphisms (SNPs) related to high levels of Lp(a) and AF. Methods This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was performed to identify studies that evaluated the association between Lp(a) levels or SNPs related to high levels of Lp(a) and AF. Observational studies with a cross-sectional, case-control, or cohort design were included in this systematic review, without limitations according to language, country, or publication type. Results Eleven observational studies including 1,246,817 patients were eligible for this systematic review. Two cross-sectional studies, 5 prospective/retrospective cohort studies, and 4 Mendelian randomization studies were analyzed. Two cross-sectional studies that compared Lp(a) levels between patients with and without AF showed conflicting results. Cohort studies that evaluated the incidence of AF according to Lp(a) levels showed different results: no association (3 studies), a positive association (1 study), and an inverse relationship (1 study). Finally, Mendelian randomization studies also showed heterogeneous results (positive association: 2 studies; inverse association: 1 study; no association: 1 study). Conclusion Although there could be an association between Lp(a) levels and AF, the results of the studies published to date are contradictory and not yet definitive. Therefore, further research should clarify this issue.
Walter Masson, Augusto Lavalle-Cobo, Leandro Barbagelata, Martin Lobo, and Juan Patricio Nogueira
Elsevier BV
Walter Masson, Leandro Barbagelata, Martín Lobo, Augusto Lavalle-Cobo, Pablo Corral, and Juan Patricio Nogueira
Springer Science and Business Media LLC
Leandro Barbagelata, Walter Masson, Pablo Corral, Augusto Lavalle-Cobo, Juan Patricio Nogueira, and Guillermo Rosa Diez
Springer Science and Business Media LLC
Walter Masson, Leandro Barbagelata, Pablo Oberti, Mariano Falconi, Augusto Lavalle-Cobo, Pablo Corral, and Juan P. Nogueira
Elsevier BV
Walter Masson, Leandro Barbagelata, Pablo Corral, Juan P. Nogueira, Augusto Lavalle-Cobo, and Alejandra Belardo
Elsevier BV
Walter Masson, Pablo Corral, Leandro Barbagelata, Augusto Lavalle-Cobo, Juan P Nogueira, Daniel Siniawski, and Kausik K Ray
Elsevier BV
Cecilia Closs, Marianela Ackerman, Walter Masson, Martin Lobo, Graciela Molinero, Augusto Lavalle-Cobo, Sophie Béliard, Florian Mourre, René Valéro, and Juan Patricio Nogueira
Springer Science and Business Media LLC
Walter Masson, Martin Lobo, Augusto Lavalle-Cobo, Gerardo Masson, Graciela Molinero, and Melina Huerín
SciELO Agencia Nacional de Investigacion y Desarrollo (ANID)
BACKGROUND
Due to their anti-inflammatory properties, it has been suggested that the use of statins could influence the evolution of influenza virus infection.
AIM
To evaluate the effect of statin therapy on mortality from influenza.
METHODS
A meta-analysis that included studies evaluating the use of statins in patients with influenza and reporting data on mortality, after searching the PubMed/MEDLINE, Embase, and Cochrane Controlled Trials databases, was performed. A random effects model was applied. The risk of bias was analyzed and a sensitivity analysis was performed.
RESULTS
Eight studies (10 independent cohorts), which included a total of 2,390,730 patients, were identified and eligible for analysis. A total of 1,146,995 subjects analyzed received statins, while 1,243,735 subjects were part of the control group. Statin therapy was associated with lower mortality (OR: 0.66; 95% CI: 0.51-0.85). The sensitivity analysis showed that the results were robust.
CONCLUSION
Our data suggest that, in a population with influenza, the use of statins was associated with a significant reduction in mortality. These results must be confirmed in future clinical trials.
Emiliano Salmeri, Alicia Elbert, Augusto M. Lavalle-Cobo, Florencia Aranguren, Hugo Sanabria, Mariano Giorgi, Ezequiel Forte, Emiliano Salmeri, Alicia Elbert, Augusto M. Lavalle-Cobo,et al.
Publicidad Permanyer, SLU
Ignacio G. Dávolos, Walter Masson, Augusto M. Lavalle-Cobo, Adriana A. Ángel, Julio Giorgini, and Enrique González-Naya
Publicidad Permanyer, SLU
Background
Patients with coronary heart disease and their families often face numerous changes in their lives. Recommendations on sexual activity (SA) should be included in the management of these patients. The objective of this study was to evaluate the degree of knowledge and professional attitude regarding the patient's SA.
Objective
A descriptive and analytical cross-sectional study was carried out. The data were obtained from a structured, virtual and anonymous survey that was carried out among cardiologists.
Results
Three hundred forty-five surveys were analyzed. In total, 63.8% considered sexual dysfunction as a cardiovascular risk marker. Likewise, 68.1% considered it relevant or very relevant to ask patients about SA. Regarding counseling, it is believed that it should be initiated primarily by the cardiologist. A more active attitude regarding the re-initiation of SA after a cardiovascular event, a greater interest in SA training, more testosterone orders and more indications of phosphodiesterase inhibitors were observed in professionals older than 60 years and male compared to younger or female physicians, respectively.
Conclusions
This study showed that the degree of knowledge of the patients about the aspects related to SA was poor. Given the relevance of the topic, we consider it important to strengthen medical education in all areas.
Walter Masson, Leandro Barbagelata, Martín Lobo, Juan P. Nogueira, Pablo Corral, and Augusto Lavalle-Cobo
Springer Science and Business Media LLC
Walter Masson, Leandro Barbagelata, Augusto Lavalle-Cobo, Martín Lobo, Gerardo Masson, Juan P. Nogueira, and Bruno Vergès
Elsevier BV
Walter Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle-Cobo, and Graciela Molinero
Informa UK Limited
Abstract Background Given the complex aetiology and a limited amount of evidence, the medical treatment (including statin use) of myocardial infarction with non-obstructive coronary artery disease (MINOCA) remains uncertain. The objective of the present study was to evaluate the effect of statin therapy on major cardiovascular events (MACE) and mortality in MINOCA patients. Methods A systematic review and meta-analysis of time-to-event outcomes were performed of studies of statin therapy on MINOCA patients, reporting data from MACE or mortality, after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A fixed-effects meta-analysis model was then applied. Results Six observational studies of statin therapy on MINOCA, involving a total of 11,171 patients, were identified and considered eligible for analysis (9129 subjects received statin therapy while 2042 patients were part of the respective control arms). Quantitative analysis (5 studies were included) showed that statin use was associated with lower mortality (HR: 0.65; 95% CI: 0.56–0.75, I 2: 0%). Also, the meta-analysis showed that statin therapy was associated with a lower incidence of MACE (HR: 0.78; 95% CI: 0.69–0.88, I 2:27%). Conclusion Our data suggest that in a population with MINOCA, the use of statin therapy results in significant reduction on MACE and mortality. These results must be confirmed in future clinical trials.
Augusto Lavalle-Cobo, Walter Masson, Martín Lobo, Gerardo Masson, and Graciela Molinero
Springer Science and Business Media LLC
Walter Masson, Augusto Lavalle-Cobo, and Juan Patricio Nogueira
MDPI AG
(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial adipose tissue (EAT) is associated with increased cardio-metabolic risks and obstructive coronary disease events in patients with T2D. (2) We performed a systematic review and meta-analysis of SGLT2-i therapy on T2D patients, reporting data on changes in EAT after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random effects or fixed effects model meta-analysis was then applied. (3) Results: A total of three studies (n = 64 patients with SGLT2-i, n = 62 with standard therapy) were included in the final analysis. SGLT2 inhibitors reduced EAT (SMD: −0.82 (−1.49; −0.15); p < 0.0001). An exploratory analysis showed that HbA1c was significantly reduced with SGLT2-i use, while body mass index was not significantly reduced with this drug. (4) Conclusions: This meta-analysis suggests that the amount of EAT is significantly reduced in T2D patients with SGLT2-i treatment.
Walter Masson, Martín Lobo, Leandro Barbagelata, Augusto Lavalle-Cobo, and Graciela Molinero
Elsevier BV
Walter Masson, Martín Lobo, Augusto Lavalle-Cobo, and Graciela Molinero
Elsevier BV
Walter Masson, Martín Lobo, Daniel Siniawski, Gerardo Masson, Augusto Lavalle-Cobo, and Graciela Molinero
Elsevier BV
Ezequiel Forte, Carolina Gómez-Martín, Paola Harwicz, Augusto Lavalle-Cobo, Diana Millán, Emiliano Salmeri, Carlos Buso, and Hugo Sanabria
Publicidad Permanyer, SLU
Objetivo: Evaluar el impacto del aislamiento social, preventivo y obligatorio sobre al aumento de peso, el nivel de actividad física, la adherencia al tratamiento y la inmunización antigripal y antineumocócica en pacientes con diabetes tipo 2 (DM2). Método: Se realizó un seguimiento telefónico de pacientes con DM2 luego de al menos 100 días de comienzo del aislamiento. Se compararon dos regiones agrupadas en relación con el número de casos: región 1, más de 150 casos/100, 000 habitantes, y región 2, más de 150 casos/100,000 habitantes. Resultados: Se contactaron 454 pacientes con DM2. El 42% reportaron incremento de peso y el 7% refirió haber aumentado más de 5 kg. En relación con la actividad física, se observó un promedio más bajo en la región 1 (367.5 [0-5698] MET/sem) que en la región 2 (720 [0-7066] MET/sem) (p = 0.0009). La adherencia al tratamiento farmacológico disminuyó en forma global, pero aumentó en las zonas de mayor circulación viral. Por otra parte, hubo un incremento de vacunación antigripal y antineumocócica, alcanzando coberturas del 80% y el 70%, respectivamente. Conclusiones: En una población de alto riesgo cardiovascular y con una prevalencia de sobrepeso/obesidad elevada, el aislamiento social, preventivo y obligatorio se asoció con ganancia de peso y menos actividad física, lo que podría resultar deletéreo sobre la salud cardiovascular de los pacientes con DM2. Por otro lado, se observan algunos aspectos positivos, como el aumento de las inmunizaciones y el incremento de la adherencia en las zonas más afectadas.